BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy

Acquired resistance of hepatocellular carcinoma (HCC) to sorafenib (SFB) is the main reason for the failure of SFB treatment of the cancer. Abnormal activation of the PI3K/AKT/mTOR pathway is important in the acquired resistance of SFB. Therefore, we investigated whether BEZ235 (BEZ) could reverse a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomed Res Int
Päätekijät: Cao, Weiya, Liu, Xueke, Zhang, Yinci, Li, Amin, Xie, Yinghai, Zhou, Shuping, Song, Li, Xu, Ruyue, Ma, Yongfang, Cai, Shiyu, Tang, Xiaolong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi 2021
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079203/
https://ncbi.nlm.nih.gov/pubmed/33987439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/5556306
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia